CD33

Target id: 2601

Nomenclature: CD33

Abbreviated Name: SIGLEC-3

Family: Other immune checkpoint proteins, CD molecules

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

   GtoImmuPdb view: OFF :     CD33 has curated GtoImmuPdb data

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 364 19q13.3 CD33 CD33 molecule
Mouse - 403 7 B4 Cd33 CD33 antigen
Rat - - 1q22 Cd33 CD33 molecule
Previous and Unofficial Names
SIGLEC3
Database Links
CATH/Gene3D
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
GenitoUrinary Development Molecular Anatomy Project
Human Protein Atlas
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia

Download all structure-activity data for this target as a CSV file

Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Affinity Units Reference
lintuzumab Hs Binding ~10.0 pKd 2
pKd ~10.0 (Kd ~1x10-10 M) [2]
vadastuximab talirine Hs Binding 9.3 pKd 5
pKd 9.3 (Kd 5x10-10 M) [5]
Description: Saturation binding in HEL 92.1.7 cells endogenously expressing human CD33.
gemtuzumab ozogamicin Hs Binding - - 1
[1]
Antibody Comments
Evidence of the effectiveness of gemtuzumab ozogamicin centers on the drug's ability to inhibit the growth of leukemic cells in vitro and in vivo [3,6-7].
Immunopharmacology Comments
CD33 (SIGLEC-3) is a myeloid cell I-type (Ig-type) lectin that binds glycans containing sialic acids [4]. Most SIGLECs inhibit immune cell activation, via immunoreceptor tyrosine-based inhibitory (ITIM) motifs in their cytosolic domains. Therefore, blockade of SIGLEC interactions restores immune cell activation, which is of interest for the treatment of myeloid leukemias. As such, CD33 is the target of approved monoclonal antibody-drug conjugate gemtuzumab ozogamicin (for CD33-positive acute myeloid leukemia) and investigational mAb lintuzumab which was a clinical candidate biologic for refractory or relapsed acute myelogenous leukemia.
Immuno Cell Type Associations
Immuno Cell Type:  Macrophages & monocytes
Cell Ontology Term:   monocyte (CL:0000576)
Comment: 
References: 
Immuno Cell Type:  Dendritic cells
Cell Ontology Term:   dendritic cell (CL:0000451)
Comment: 
References: 
Immuno Cell Type:  Granulocytes
Cell Ontology Term:   granulocyte (CL:0000094)
Comment: 
References: 
Immuno Process Associations
Immuno Process:  Inflammation
Immuno Process ID:  2
Comment: 
GO Annotation:  Associated to GO processes
GO Processes:  neutrophil degranulation (GO:0043312) TAS
References: 
Immuno Process:  Immune regulation
Immuno Process ID:  6
Comment: 
GO Annotation:  Associated to GO processes
GO Processes:  regulation of immune response (GO:0050776) TAS
References: 
Immuno Process:  Cellular signalling
Immuno Process ID:  11
Comment: 
GO Annotation:  Associated to GO processes
GO Processes:  neutrophil degranulation (GO:0043312) TAS
References: 

References

Show »

1. Bernstein ID. (2000) Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia14 (3): 474-5. [PMID:10720144]

2. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. (1992) Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res.52 (24): 6761-7. [PMID:1458463]

3. Frankel AE, Sievers EL, Scheinberg DA. (2000) Cell surface receptor-targeted therapy of acute myeloid leukemia: a review. Cancer Biother. Radiopharm.15 (5): 459-76. [PMID:11155818]

4. Garnache-Ottou F, Chaperot L, Biichle S, Ferrand C, Remy-Martin JP, Deconinck E, de Tailly PD, Bulabois B, Poulet J, Kuhlein E et al.. (2005) Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood105 (3): 1256-64. [PMID:15388576]

5. Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, Stone I, Ryan MC, Sussman D, Lyon RP et al.. (2013) SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood122 (8): 1455-63. [PMID:23770776]

6. McGavin JK, Spencer CM. (2001) Gemtuzumab ozogamicin. Drugs61 (9): 1317-22; discussion 1323-4. [PMID:11511025]

7. van Der Velden VH, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS, van Dongen JJ. (2001) Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood97 (10): 3197-204. [PMID:11342449]

How to cite this page

CD molecules: CD33. Last modified on 18/08/2017. Accessed on 18/10/2017. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2601.